Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 79
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
BMC Vet Res ; 17(1): 149, 2021 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-33827566

RESUMO

BACKGROUND: Topical ophthalmic atropine sulfate is an important part of the treatment protocol in equine uveitis. Frequent administration of topical atropine may cause decreased intestinal motility and colic in horses due to systemic exposure. Atropine pharmacokinetics are unknown in horses and this knowledge gap could impede the use of atropine because of the presumed risk of unwanted effects. Additional information could therefore increase safety in atropine treatment. RESULTS: Atropine sulfate (1 mg) was administered in two experiments: In part I, atropine sulfate was administered intravenously and topically (manually as eye drops and through a subpalpebral lavage system) to six horses to document atropine disposition. Blood-samples were collected regularly and plasma was analyzed for atropine using UHPLC-MS/MS. Atropine plasma concentration was below lower limit of quantification (0.05 µg/L) within five hours, after both topical and IV administration. Atropine data were analyzed by means of population compartmental modeling and pharmacokinetic parameters estimated. The typical value was 1.7 L/kg for the steady-state volume of distribution. Total plasma clearance was 1.9 L/h‧kg. The bioavailability after administration of an ophthalmic preparation as an eye drop or topical infusion were 69 and 68%, respectively. The terminal half-life was short (0.8 h). In part II, topical ophthalmic atropine sulfate and control treatment was administered to four horses in two dosing regimens to assess the effect on gastro-intestinal motility. Borborygmi-frequency monitored by auscultation was used for estimation of gut motility. A statistically significant decrease in intestinal motility was observed after administration of 1 mg topical ophthalmic atropine sulfate every three hours compared to control, but not after administration every six hours. Clinical signs of colic were not observed under any of the treatment protocols. CONCLUSIONS: Taking the plasma exposure after topical administration into consideration, data and simulations indicate that eye drops administrated at a one and three hour interval will lead to atropine accumulation in plasma over 24 h but that a six hour interval allows total washout of atropine between two topical administrations. If constant corneal and conjunctival atropine exposure is required, a topical constant rate infusion at 5 µg/kg/24 h offers a safe alternative.


Assuntos
Atropina/farmacocinética , Motilidade Gastrointestinal/efeitos dos fármacos , Cavalos/sangue , Parassimpatolíticos/farmacocinética , Animais , Atropina/administração & dosagem , Atropina/sangue , Disponibilidade Biológica , Feminino , Meia-Vida , Injeções Intravenosas , Masculino , Soluções Oftálmicas , Parassimpatolíticos/administração & dosagem , Parassimpatolíticos/sangue
2.
Acta Anaesthesiol Scand ; 61(6): 636-640, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28444856

RESUMO

BACKGROUND: There is increasing interest in the use of intranasal naloxone to reverse adverse opioid effects during management of procedural pain in children and in adults after overdose. There are limited data on the pharmacokinetics of intranasal naloxone so in this study we aimed to detail the pharmacokinetic profile of the commercially marketed injectable solution of naloxone 0.4 mg/ml when administered as an intranasal spray. METHODS: Twenty healthy volunteers received naloxone as an intranasal spray at a dose of 10 µg/kg. Venous blood sampling was carried out for 90 min after administration to determine the time profile of the plasma concentrations of using tandem mass spectrometry. Pharmacokinetic parameters were calculated using a one-compartment model. RESULTS: Median time to maximum naloxone concentration (Tmax) was 14.5 (95% CI: 9.0-16.5) min, mean maximum naloxone concentration (Cmax) was 1.09 ± 0.56 ng/ml and mean AUC0-90 min was 37.1 ± 15.0 ng*min/ml. Elimination half-life estimated from the median concentration data was 28.2 min. CONCLUSION: Our results show a faster uptake of intranasal naloxone to maximum concentration compared with previous studies although with a marked variation in maximum concentration. The findings are consistent with our clinical experience of the time profile for reversing the effects of sufentanil sedation in children.


Assuntos
Naloxona/administração & dosagem , Naloxona/farmacocinética , Antagonistas de Entorpecentes/administração & dosagem , Antagonistas de Entorpecentes/farmacocinética , Administração Intranasal , Adulto , Área Sob a Curva , Cromatografia Líquida de Alta Pressão , Estudos Cross-Over , Feminino , Meia-Vida , Voluntários Saudáveis , Humanos , Hipnóticos e Sedativos/antagonistas & inibidores , Masculino , Pessoa de Meia-Idade , Naloxona/efeitos adversos , Antagonistas de Entorpecentes/efeitos adversos , Sprays Nasais , Sufentanil/antagonistas & inibidores , Espectrometria de Massas em Tandem , Adulto Jovem
3.
Rapid Commun Mass Spectrom ; 30(7): 982-4, 2016 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-26969941

RESUMO

RATIONALE: The issue of illicit performance enhancement spans human and animal sport in presumably equal measure, with prohibited substances and methods of doping conveying both ways. Due to the proven capability of unbound ionic cobalt (Co(2) (+) ) to stimulate erythropoiesis in humans, both human and equine anti-doping regulations have listed cobalt as a banned substance, and in particular in horse drug testing, thresholds for cobalt concentrations applying to plasma and urine have been suggested or established. Recent reports about the finding of substantial amounts of undeclared nickel in arguably licit performance- and recovery-supporting products raised the question whether the ionic species of this transition metal (Ni(2) (+) ), which exhibits similar prolyl hydroxylase inhibiting properties to Co(2) (+) , has been considered as a substitute for cobalt in doping regimens. METHODS: Therefore, a pilot study with 200 routine post-competition doping control horse urine samples collected from animals participating in equestrian, gallop, and trotting in Europe was conducted to provide a first dataset on equine urinary Ni(2) (+) concentrations. All specimens were analyzed by conventional inductively coupled plasma mass spectrometry (ICP-MS) to yield quantitative data for soluble nickel. RESULTS: Concentrations ranging from below the assay's limit of quantification (LOQ, 0.5 ng/mL) up to 33.4 ng/mL with a mean value (± standard deviation) of 6.1 (±5.1) ng/mL were determined for the total nickel content. CONCLUSIONS: In horses, nickel is considered a micronutrient and feed supplements containing nickel are available; hence, follow-up studies are deemed warranted to consolidate potential future threshold levels concerning urine and blood nickel concentrations in horses using larger sets of samples for both matrices and to provide in-depth insights by conducting elimination studies with soluble Ni(2) (+) -salt species. Copyright © 2016 John Wiley & Sons, Ltd.


Assuntos
Dopagem Esportivo , Cavalos/fisiologia , Níquel/urina , Animais , Feminino , Masculino , Espectrometria de Massas , Projetos Piloto
4.
J Vet Pharmacol Ther ; 39(3): 255-63, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26542753

RESUMO

The cortisol response to glucocorticoid intervention has, in spite of several studies in horses, not been fully characterized with regard to the determinants of onset, intensity and duration of response. Therefore, dexamethasone and cortisol response data were collected in a study applying a constant rate infusion regimen of dexamethasone (0.17, 1.7 and 17 µg/kg) to six Standardbreds. Plasma was analysed for dexamethasone and cortisol concentrations using UHPLC-MS/MS. Dexamethasone displayed linear kinetics within the concentration range studied. A turnover model of oscillatory behaviour accurately mimicked cortisol data. The mean baseline concentration range was 34-57 µg/L, the fractional turnover rate 0.47-1.5 1/h, the amplitude parameter 6.8-24 µg/L, the maximum inhibitory capacity 0.77-0.97, the drug potency 6-65 ng/L and the sigmoidicity factor 0.7-30. This analysis provided a better understanding of the time course of the cortisol response in horses. This includes baseline variability within and between horses and determinants of the equilibrium concentration-response relationship. The analysis also challenged a protocol for a dexamethasone suppression test design and indicated future improvement to increase the predictability of the test.


Assuntos
Dexametasona/farmacologia , Glucocorticoides/farmacologia , Cavalos/sangue , Hidrocortisona/sangue , Animais , Dexametasona/administração & dosagem , Dexametasona/sangue , Feminino , Glucocorticoides/administração & dosagem , Glucocorticoides/sangue , Masculino
5.
Equine Vet J ; 47 Suppl 48: 22, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26375998

RESUMO

REASONS FOR PERFORMING STUDY: Hypoglycin A (HG) appears to cause atypical myopathy (AM), but to our knowledge, detection of HG in affected and unaffected horses and concurrently in plants that they were exposed to has not previously been reported. OBJECTIVES: To investigate HG in samples from horses exposed to Acer pseudoplatanus (European sycamore maple) and in such plant material, at the time of clinical cases of AM in the herd. STUDY DESIGN: Cross-sectional study. METHODS: Blood was collected from 2 horses with AM and 22 clinically healthy co-grazing horses in 2 Swedish farms within one week of onset of signs (May 2014) and one month later, after horses were moved to other pastures. Ten healthy control horses from unaffected farms were sampled once. Samaras, seedlings, flowers and leaves from Acer pseudoplatanus and from Acer platanoides L (Norway maple) were collected from affected pastures. Hypoglycin A was analysed using chemical derivatisation with dansyl chloride (DNS) and ultra high performance liquid chromatography-tandem mass spectrometry. Hypoglycin A was detected as derivatised compound HG-DNS [M+H]+ with selected reaction monitoring. RESULTS: Hypoglycin A was detected in the horses affected with AM, and also in 20 out of 22 co-grazing horses. One month later, a surviving case horse and 9/20 co-grazing horses were still positive for HG. Controls from other farms were negative for HG. Hypoglycin A was detected in plant material from Acer pseudoplatanus, but not from Acer platanoides L. CONCLUSIONS: Horses grazing in pastures with HG-containing Acer pseudoplatanus were positive for HG in blood, and some showed severe signs of myopathy. Ethical animal research: Ethical consent for blood sampling was granted (C113/11) and horse owners gave their informed consent to inclusion of horses in the study. SOURCE OF FUNDING: National Veterinary Institute, Sweden. Competing interests: None declared.

6.
J Vet Pharmacol Ther ; 38(3): 235-42, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25366540

RESUMO

Detection times and screening limits (SL) are methods used to ensure that the performance of horses in equestrian sports is not altered by drugs. Drug concentration-response relationship and knowledge of concentration-time profiles in both plasma and urine are required. In this study, dexamethasone plasma and urine concentration-time profiles were investigated. Endogenous hydrocortisone plasma concentrations and their relationship to dexamethasone plasma concentrations were also explored. A single dose of dexamethasone-21-isonicotinate suspension (0.03 mg/kg) was administered intramuscularly to six horses. Plasma was analysed for dexamethasone and hydrocortisone and urine for dexamethasone, using UPLC-MS/MS. Dexamethasone was quantifiable in plasma for 8.3 ± 2.9 days (LLOQ: 0.025 µg/L) and in urine for 9.8 ± 3.1 days (LLOQ: 0.15 µg/L). Maximum observed dexamethasone concentration in plasma was 0.61 ± 0.12 µg/L and in urine 4.2 ± 0.9 µg/L. Terminal plasma half-life was 38.7 ± 19 h. Hydrocortisone was significantly suppressed for 140 h. The plasma half-life of hydrocortisone was 2.7 ± 1.3 h. Dexamethasone potency, efficacy and sigmoidicity factor for hydrocortisone suppression were 0.06 ± 0.04 µg/L, 0.95 ± 0.04 and 6.2 ± 4.6, respectively. Hydrocortisone suppression relates to the plasma concentration of dexamethasone. Thus, determination of irrelevant plasma concentrations and SL is possible. Future research will determine whether hydrocortisone suppression can be used as a biomarker of the clinical effect of dexamethasone.


Assuntos
Benzamidas/farmacologia , Cavalos/metabolismo , Hidrocortisona/sangue , Animais , Benzamidas/administração & dosagem , Benzamidas/sangue , Benzamidas/urina , Cavalos/fisiologia , Hidrocortisona/antagonistas & inibidores , Injeções Intramusculares/veterinária , Masculino
7.
Anal Bioanal Chem ; 405(25): 8285-94, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23877183

RESUMO

The discovery and implementation of the long-term metabolite of metandienone, namely 17ß-hydroxymethyl-17α-methyl-18-norandrost-1,4,13-trien-3-one, to doping control resulted in hundreds of positive metandienone findings worldwide and impressively demonstrated that prolonged detection periods significantly increase the effectiveness of sports drug testing. For oxandrolone and other 17-methyl steroids, analogs of this metabolite have already been described, but comprehensive characterization and pharmacokinetic data are still missing. In this report, the synthesis of the two epimeric oxandrolone metabolites-17ß-hydroxymethyl-17α-methyl-18-nor-2-oxa-5α-androsta-13-en-3-one and 17α-hydroxymethyl-17ß-methyl-18-nor-2-oxa-5α-androsta-13-en-3-one-using a fungus (Cunninghamella elegans) based protocol is presented. The reference material was fully characterized by liquid chromatography nuclear magnetic resonance spectroscopy and high resolution/high accuracy mass spectrometry. To ensure a specific and sensitive detection in athlete's urine, different analytical approaches were followed, such as liquid chromatography-tandem mass spectrometry (QqQ and Q-Orbitrap) and gas chromatography-tandem mass spectrometry, in order to detect and identify the new target analytes. The applied methods have demonstrated good specificity and no significant matrix interferences. Linearity (R(2) > 0.99) was tested, and precise results were obtained for the detection of the analytes (coefficient of variation <20%). Limits of detection (S/N) for confirmatory and screening analysis were estimated at 1 and 2 ng/mL of urine, respectively. The assay was applied to oxandrolone post-administration samples to obtain data on the excretion of the different oxandrolone metabolites. The studied specimens demonstrated significantly longer detection periods (up to 18 days) for the new oxandrolone metabolites compared to commonly targeted metabolites such as epioxandrolone or 18-nor-oxandrolone, presenting a promising approach to improve the fight against doping.


Assuntos
Anabolizantes/metabolismo , Anabolizantes/urina , Cromatografia Gasosa-Espectrometria de Massas/métodos , Oxandrolona/metabolismo , Oxandrolona/urina , Detecção do Abuso de Substâncias/métodos , Anabolizantes/síntese química , Anabolizantes/química , Cromatografia Líquida/métodos , Dopagem Esportivo , Humanos , Limite de Detecção , Masculino , Pessoa de Meia-Idade , Oxandrolona/análogos & derivados , Oxandrolona/síntese química , Espectrometria de Massas em Tandem/métodos
8.
Res Vet Sci ; 95(1): 231-7, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23540608

RESUMO

The pharmacokinetics and effects of the opioid methadone on behaviour, arterial blood pressure, heart rate and haematocrit were studied in goats. Two goats received methadone (0.2mg/kg) intravenously and the terminal half-life was 88 and 91 min, the volume of distribution 8.4 and 6.1L/kg, and clearance 86 and 123 mL/min/kg. In a crossover study eight goats received methadone (0.6 mg/kg) or 0.15M NaCl subcutaneously (SC). After SC administration bioavailability was complete and the terminal half-life was 215 ± 84 min (mean ± SD), Tmax 31 ± 15 min and Cmax 45 ±11 ng/mL. Blood pressure and haematocrit increased while heart rate did not change. The goats did not ruminate and they climbed, scratched, gnawed and showed tail-flicking after SC methadone in contrast to NaCl administration. The use of methadone in goats may be restricted due to the inhibition of rumination and the rather short half-life.


Assuntos
Pressão Sanguínea/efeitos dos fármacos , Cabras/metabolismo , Metadona/sangue , Metadona/farmacocinética , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/sangue , Analgésicos Opioides/farmacocinética , Animais , Área Sob a Curva , Comportamento Animal/efeitos dos fármacos , Comportamento Animal/fisiologia , Pressão Sanguínea/fisiologia , Estudos Cross-Over , Feminino , Meia-Vida , Frequência Cardíaca/efeitos dos fármacos , Frequência Cardíaca/fisiologia , Hematócrito/veterinária , Metadona/administração & dosagem , Projetos Piloto , Distribuição Aleatória
9.
Eur J Clin Pharmacol ; 69(2): 197-207, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22732766

RESUMO

PURPOSE: To evaluate the pharmacokinetic parameters of a single oral dose of vardenafil in patients with pulmonary hypertension (PH). METHODS: Sixteen patients with PH received vardenafil in single oral doses (20, 10 or 5 mg), and repeated blood sampling for up to 9 h was performed. Vardenafil plasma concentration was determined using liquid chromatography tandem mass spectrometry. Pharmacokinetic parameters were calculated using model-independent analysis. RESULTS: The plasma vardenafil concentration increased rapidly and exhibited a median time to maximum plasma concentration (t(max)) of 1 h and a mean elimination half-life (t(1/2)) of 3.4 h. The geometric mean and standard deviation of (1) the peak plasma concentration (C(max)) was 21.4 ± 1.7 µg/L, (2) the normalized C(max) (C(max, norm)) 79.1 ± 1.6 g/L, (3) the area under the time-concentration curve (AUC) 71.5 ± 1.6 µg · h/L and (4) the normalized AUC (AUC(norm)) 261.6 ± 1.7 g · h/L. Patients co-medicated with bosentan reached t(max) later and had a 90% reduction of C(max), C(max, norm), AUC and AUC(norm). CONCLUSION: The pharmacokinetic profile of vardenafil overall revealed considerable inter-individual variability in patients with PH. Co-medication with bosentan resulted in a pharmacokinetic drug interaction, leading to significantly decreased plasma concentrations of vardenafil. Therapeutic drug monitoring for individual dose optimization may be warranted.


Assuntos
Hipertensão Pulmonar/sangue , Imidazóis/farmacocinética , Inibidores da Fosfodiesterase 5/farmacocinética , Piperazinas/farmacocinética , Vasodilatadores/farmacocinética , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/fisiopatologia , Imidazóis/sangue , Masculino , Pessoa de Meia-Idade , Inibidores da Fosfodiesterase 5/sangue , Piperazinas/sangue , Sulfonas/sangue , Sulfonas/farmacocinética , Triazinas/sangue , Triazinas/farmacocinética , Dicloridrato de Vardenafila , Vasodilatadores/sangue
10.
J Vet Pharmacol Ther ; 34(1): 64-9, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21219346

RESUMO

The pharmacokinetics and analgesic effect of the nonsteroidal anti-inflammatory drug meloxicam (0.5 mg/kg) in goats were investigated. In a randomized, cross-over design the pharmacokinetic parameters were investigated in adult goats (n = 8) after single intravenous and oral administration. The analgesic effect was evaluated in kids using a randomized, placebo controlled and blinded protocol. Kids received meloxicam (n = 6) once daily and their siblings (n = 5) got isotonic NaCl intramuscularly while still anaesthetized after cautery disbudding and injections were repeated on three consecutive days. In the adult goats after intravenous administration the terminal half-life was 10.9 ± 1.7 h, steady-state volume of distribution was 0.245 ± 0.06 L/kg, and total body clearance was 17.9 ± 4.3 mL/h/kg. After oral administration bioavailability was 79 ± 19%, C(max) was 736 ± 184 ng/mL, T(max) was 15 ±5 h, although the terminal half-life was similar to the intravenous value, 11.8 ± 1.7 h. Signs of pain using a visual analogue scale were smaller in kids treated with meloxicam compared with kids treated with placebo on the first day after disbudding, but subsequently no difference in pain was noticeable. Plasma cortisol and glucose concentrations did not differ between the two groups.


Assuntos
Cabras , Dor/veterinária , Procedimentos Cirúrgicos Operatórios/veterinária , Tiazinas/farmacocinética , Tiazinas/uso terapêutico , Tiazóis/farmacocinética , Tiazóis/uso terapêutico , Animais , Anti-Inflamatórios não Esteroides/farmacocinética , Anti-Inflamatórios não Esteroides/uso terapêutico , Área Sob a Curva , Glicemia , Doenças das Cabras/tratamento farmacológico , Meia-Vida , Hidrocortisona/sangue , Meloxicam , Dor/sangue , Dor/tratamento farmacológico , Dor/etiologia , Procedimentos Cirúrgicos Operatórios/efeitos adversos
11.
Xenobiotica ; 40(8): 558-68, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20583894

RESUMO

Hepatobiliary transporters efficiently shunt rosuvastatin from the blood stream, into the hepatocyte, followed by transporter-mediated excretion into the bile ducts. This study aimed at investigating the contribution of sinusoidal versus canalicular transport on the pharmacokinetics of an intrajejunal dose of 80 mg rosuvastatin in pigs (control group, n = 2 + 6). The transport inhibitors, rifampicin (20 mg/kg, n = 6) and imatinib (14 mg/kg, n = 6), were administered as 2-h long intravenous infusions. Plasma samples were withdrawn from the portal and hepatic vein simultaneously during 5 h along with bile sample collection. Rifampicin reduced the hepatic extraction of rosuvastatin by 35% and the area under the curve in the hepatic vein compartment increased by a factor of 6.3 (95% confidence intervals (CI): 3.1-32, P value <0.01). The increase in the portal vein compartment was less pronounced than in the hepatic vein, 2.0-fold (95% CI: 1.1-3.8, P value <0.05), suggesting that the inhibition was predominantly located in the liver rather than in the intestine and suggesting inhibition if sinusoidal transport. In contrast, no effect on the pharmacokinetics of rosuvastatin was observed following concomitant administration with imatinib possibly due to insufficient concentration of the inhibitor inside the hepatocyte. Rifampicin significantly affected the hepatobiliary transport of rosuvastatin, however imatinib did not alter the plasma exposure of rosuvastatin.


Assuntos
Fluorbenzenos/farmacocinética , Inibidores de Hidroximetilglutaril-CoA Redutases/farmacocinética , Fígado/metabolismo , Piperazinas/administração & dosagem , Pirimidinas/administração & dosagem , Pirimidinas/farmacocinética , Rifampina/administração & dosagem , Sulfonamidas/farmacocinética , Administração Oral , Benzamidas , Bile/efeitos dos fármacos , Relação Dose-Resposta a Droga , Interações Medicamentosas , Mesilato de Imatinib , Fígado/efeitos dos fármacos , Rosuvastatina Cálcica
12.
J Vet Pharmacol Ther ; 30(3): 194-200, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17472650

RESUMO

The pharmacokinetics of the histamine H(1)-antagonist cetirizine and the effects of pretreatment with the antiparasitic macrocyclic lactone ivermectin on the pharmacokinetics of cetirizine were studied in horses. After oral administration of cetirizine at 0.2 mg/kg bw, the mean terminal half-life was 3.4 h (range 2.9-3.7 h) and the maximal plasma concentration 132 ng/mL (101-196 ng/mL). The time to reach maximal plasma concentration was 0.7 h (0.5-0.8 h). Ivermectin (0.2 mg/kg bw) given orally 1.5 h before cetirizine did not affect its pharmacokinetics. However, ivermectin pretreatment 12 h before cetirizine increased the area under the plasma concentration-time curve by 60%. The maximal plasma concentration, terminal half-life and mean residence time also increased significantly following the 12 h pretreatment. Ivermectin is an inhibitor of P-glycoprotein, which is a major drug efflux transporter in cellular membranes at various sites. The elevated plasma levels of cetirizine following the pretreatment with ivermectin may mainly be due to decreased renal secretion, related to inhibition of the P-glycoprotein in the proximal tubular cells of the kidney. The pharmacokinetic properties of cetirizine have characteristics which are suitable for an antihistamine, and this substance may be a useful drug in horses.


Assuntos
Antiparasitários/farmacologia , Cetirizina/farmacocinética , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Cavalos/metabolismo , Ivermectina/farmacologia , Administração Oral , Animais , Antiparasitários/administração & dosagem , Antiparasitários/sangue , Área Sob a Curva , Cetirizina/administração & dosagem , Cetirizina/sangue , Interações Medicamentosas , Feminino , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/sangue , Ivermectina/administração & dosagem , Ivermectina/sangue , Masculino
13.
J Vet Pharmacol Ther ; 30(3): 249-56, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17472657

RESUMO

The pharmacokinetics and the effects of the opioid buprenorphine on behavior, cardiovascular parameters, plasma concentrations of cortisol and vasopressin were studied in the goat. After intravenous injection at a dosage of 0.02 mg/kg bw, the terminal half-life was 73.8+/-19.9 min (mean+/-SD), the apparent volume of distribution 5.22+/-1.01 L/kg, and total body clearance 79.1+/-18.5 mL/min/kg. After intramuscular administration of buprenorphine at the same dosage, bioavailability was complete and clearance was 54.7+/-16.6 mL/min/kg. Heart rate, blood pressure and concentrations of cortisol and vasopressin in plasma increased after drug administration. The goats became agitated and stopped ruminating. The effects were more pronounced the first time the animals received the drug, especially the influence on the hormone levels. The concentrations of cortisol and vasopressin in plasma remained unaffected after the second dose despite a wash-out period of 3-6 weeks. Buprenorphine may be an unsuitable drug in goats because of the profound inhibition of rumination and the agitation it causes. The short half-life of buprenorphine may limit its use if long-term analgesia is required but be advantageous if a short acting drug is desirable.


Assuntos
Analgésicos Opioides/farmacocinética , Buprenorfina/farmacocinética , Cabras/metabolismo , Lactação , Analgésicos Opioides/administração & dosagem , Analgésicos Opioides/sangue , Animais , Área Sob a Curva , Comportamento Animal , Buprenorfina/administração & dosagem , Buprenorfina/sangue , Estudos Cross-Over , Feminino , Frequência Cardíaca , Hidrocortisona/sangue , Injeções Intramusculares/veterinária , Injeções Intravenosas/veterinária , Vasopressinas/sangue
14.
J Vet Pharmacol Ther ; 29(2): 129-35, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16515667

RESUMO

The pharmacokinetics and the effects on inhibition of histamine-induced cutaneous wheal formation of the histamine H1-antagonist fexofenadine were studied in horse. The effect of ivermectin pretreatment on the pharmacokinetics of fexofenadine was also examined. After intravenous infusion of fexofenadine at 0.7 mg/kg bw the mean terminal half-life was 2.4 h (range: 2.0-2.7 h), the apparent volume of distribution 0.8 L/kg (0.5-0.9 L/kg), and the total body clearance 0.8 L/h/kg (0.6-1.2 L/h/kg). After oral administration of fexofenadine at 10 mg/kg bw bioavailability was 2.6% (1.9-2.9%). Ivermectin pretreatment (0.2 mg/kg, p.o.) 12 h before oral fexofenadine decreased the bioavailability to 1.5% (1.4-2.1%). In addition, the area under the plasma concentration-time curve decreased 27%. Ivermectin did not affect the pharmacokinetics of i.v. administered fexofenadine. Ivermectin may influence fexofenadine absorption by interfering in intestinal efflux and influx pumps, such as P-glycoprotein and the organic anion transport polypeptide family. Oral and i.v. fexofenadine significantly decreased histamine-induced wheal formation, with a maximal duration of 6 h. A pharmacokinetic/pharmacodynamic link model indicated that fexofenadine in horse has antihistaminic effects at low plasma concentrations (EC50 = 16 ng/mL). However, oral treatments of horses with fexofenadine may not be suitable due to the low bioavailability.


Assuntos
Antiparasitários/farmacologia , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Ivermectina/farmacologia , Terfenadina/análogos & derivados , Animais , Área Sob a Curva , Disponibilidade Biológica , Interações Medicamentosas , Feminino , Meia-Vida , Antagonistas dos Receptores Histamínicos H1/sangue , Antagonistas dos Receptores Histamínicos H1/farmacologia , Cavalos , Terfenadina/sangue , Terfenadina/farmacocinética , Terfenadina/farmacologia
15.
Int J Clin Pharmacol Ther ; 44(2): 71-9, 2006 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-16502766

RESUMO

OBJECTIVE: To investigate the in vivo intestinal absorption mechanism(s) and systemic availability of fexofenadine in the jejunum, ileum and colon in humans. METHOD: A single dose of fexofenadine hydrochloride (60 mg as solution) was applied under fasting conditions, either alone or directly after a solution of erythromycin lactobionate (corresponding to a dose of 250 mg erythromycin), to the jejunum, ileum and colon in 6 healthy volunteers (3 male and 3 female) using a regional intubation dosing technology (Bioperm AB, Lund, Sweden). A total of 36 fexofenadine administrations were performed. The administration of fexofenadine to the specified location either alone or in combination with erythromycin was conducted in a randomized manner on 2 consecutive days with a 5-day washout period between doses. RESULTS: The plasma AUC for fexofenadine (mean +/- SEM) was higher (2.7-to 2.3-fold, p < 0.001) after application to the jejunum (1090 +/- 134 h x ng/ml) than to the ileum (404 +/- 102 h x ng/ml) or colon (476 +/- 212 h x ng/ml). No significant differences were found between application to the ileum and colon. The administration of erythromycin affected the absorption rate after jejunal application with a prolonged tmax from a median of 40 min (range 10-90 min) to a median of 3 hours (range 10-180 min) (p = 0.009). A change in tmax was not observed with application to the ileum and colon. The concomitant administration of erythromycin in the jejunum tended to increase the plasma AUC of fexofenadine from 1090 +/- 134 to 1750 +/- 305 h x ng/ml (p = 0.069). CONCLUSIONS: The systemic availability of fexofenadine was significantly higher after jejunal administration in accordance with a low permeability compound. The effects of erythromycin suggest that absorption of fexofenadine involves an uptake transport in addition to passive diffusion in the jejunum and predominantly passive diffusion in the ileum and colon.


Assuntos
Eritromicina/farmacologia , Absorção Intestinal/efeitos dos fármacos , Mucosa Intestinal/metabolismo , Intubação/métodos , Terfenadina/análogos & derivados , Administração Oral , Adulto , Antialérgicos/administração & dosagem , Antialérgicos/sangue , Antialérgicos/farmacocinética , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Área Sob a Curva , Disponibilidade Biológica , Cápsulas , Colo/metabolismo , Sinergismo Farmacológico , Eritromicina/administração & dosagem , Feminino , Humanos , Íleo/metabolismo , Jejuno/metabolismo , Masculino , Polietileno , Valores de Referência , Terfenadina/administração & dosagem , Terfenadina/sangue , Terfenadina/farmacocinética , Fatores de Tempo
16.
Vet Dermatol ; 15(3): 152-8, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15214951

RESUMO

The pharmacokinetic properties of clemastine were investigated in six healthy dogs and compared with the effect of the drug recorded as inhibition of wheal formation induced by intradermal injections of histamine. Clemastine clearance was high (median: 2.1 L h(-1) kg(-1)) and the volume of distribution large (13.4 L kg(-1)). The half-life after intravenous administration was 3.8 h and the plasma protein binding level in vitro was 98%. After oral administration, the bioavailability was only 3%. Given intravenously, clemastine (0.1 mg kg(-1)) inhibited wheal formation completely for 7 h, whereas the effect after oral administration (0.5 mg kg(-1)) was minor. The data show that most dosage regimens suggested in the literature for the oral administration of clemastine to dogs are likely to give too low a systemic exposure of the drug to allow effective therapy.


Assuntos
Clemastina/farmacocinética , Clemastina/uso terapêutico , Doenças do Cão/prevenção & controle , Cães/metabolismo , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Hipersensibilidade/veterinária , Administração Oral , Animais , Área Sob a Curva , Disponibilidade Biológica , Clemastina/administração & dosagem , Clemastina/sangue , Estudos Cross-Over , Doenças do Cão/induzido quimicamente , Feminino , Histamina , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/sangue , Hipersensibilidade/etiologia , Hipersensibilidade/prevenção & controle , Injeções Intravenosas/veterinária
17.
J Vet Pharmacol Ther ; 26(2): 151-7, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12667185

RESUMO

Clemastine is an H1 antagonist used in certain allergic disorders in humans and tentatively also in horses, although the pharmacology of the drug in this species has not yet been investigated. In the present study we determined basic pharmacokinetic parameters and compared the effect of the drug measured as inhibition of histamine-induced cutaneous wheal formation in six horses. The most prominent feature of drug disposition after intravenous dose of 50 microg/kg bw was a very rapid initial decline in plasma concentration, followed by a terminal phase with a half-life of 5.4 h. The volume of distribution was large, Vss = 3.8 L/kg, and the total body clearance 0.79 L/h kg. Notably, oral bioavailability was only 3.4%. There was a strong relationship between plasma concentrations and effect. The effect maximum (measured as reduction in histamine-induced cutaneous wheal formation) was 65% (compared with controls where saline was injected) and the effect duration after i.v. dose was approximately 5 h. The effect after oral dose of 200 microg/kg was minor. The results indicate that clemastine is not appropriate for oral administration to horses because of low bioavailability. When using repeated i.v. administration, the drug has to be administered at least three to four times daily to maintain therapeutic plasma concentrations because of the short half-life. However, if sufficient plasma concentrations are maintained the drug is efficacious in reducing histamine-induced wheal formations.


Assuntos
Clemastina/farmacocinética , Antagonistas dos Receptores Histamínicos H1/farmacocinética , Cavalos/metabolismo , Administração Oral , Animais , Clemastina/administração & dosagem , Clemastina/sangue , Clemastina/farmacologia , Estudos Cross-Over , Feminino , Antagonistas dos Receptores Histamínicos H1/administração & dosagem , Antagonistas dos Receptores Histamínicos H1/sangue , Antagonistas dos Receptores Histamínicos H1/farmacologia , Injeções Intravenosas/veterinária , Masculino
18.
J Chromatogr B Biomed Sci Appl ; 763(1-2): 121-31, 2001 Nov 05.
Artigo em Inglês | MEDLINE | ID: mdl-11710570

RESUMO

Ketobemidone and five of its phase I metabolites were identified in the urine of four patients post intravenous administration of Ketogan Novum. Furthermore, indications of the presence of the glucuronide conjugates of ketobemidone and norketobemidone is presented. Both hydrolyzed (beta-glucuronidase) and unhydrolyzed human urine was extracted on a mixed-mode slightly polar cation-exchange SPEC cartridge prior to analysis with LC-ESI-MS-MS. The phase I metabolites were identified by comparison of their daughter spectra with those of synthesized standards. The glucuronides were identified by their molecular mass and interpretation of the daughter spectra, as no standards were available for these compounds.


Assuntos
Analgésicos Opioides/urina , Cromatografia Líquida de Alta Pressão/métodos , Cromatografia por Troca Iônica/métodos , Espectrometria de Massas/métodos , Meperidina/análogos & derivados , Meperidina/urina , Analgésicos Opioides/química , Humanos , Meperidina/química , Peso Molecular
19.
J Chromatogr A ; 922(1-2): 303-11, 2001 Jul 13.
Artigo em Inglês | MEDLINE | ID: mdl-11486876

RESUMO

(-)-2,3:4,6-Di-O-isopropylidene-2-keto-L-gulonic acid [(-)-DIKGA] has been introduced as a chiral counter ion in non-aqueous capillary electrophoresis. High enantioresolutions (R(s)> or =3) were obtained for amines, e.g., pronethalol, labetalol and bambuterol. Methanol containing NaOH and (-)-DIKGA was used as the background electrolyte. The counter ion concentration and the nature of the injection medium were found to affect the chiral separation. Covalent coating of the fused-silica capillary reduced the electro-osmotic flow resulting in improved enantioresolutions.


Assuntos
Aminas/isolamento & purificação , Compostos Bicíclicos Heterocíclicos com Pontes/química , Eletroforese Capilar/métodos , Indicadores e Reagentes/química , Açúcares Ácidos/química , Reprodutibilidade dos Testes , Estereoisomerismo
20.
Electrophoresis ; 20(7): 1527-32, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10424476

RESUMO

Capillary electrophoresis was combined with highly sensitive microelectrospray-tandem mass spectrometry to simultaneously detect classical small molecule neurotransmitters as well as neuropeptides from discrete regions of the marmoset brain. A mixture of four classical neurotransmitters (glutamate, gamma-aminobutyric acid, acetylcholine, dopamine) and four neuropeptides (neurotensin, methionine-enkephalin, leucine-enkephalin and substance P 1-7) was studied to optimize the capillary electrophoresis conditions for separation, injection volume, and analysis time. Gamma-aminopropyltriethoxysilane-coated capillaries and acetic acid electrolytes were used to avoid interactions between the sample and the capillary surface and to obtain a high anodic electroosmotic flow, which resulted in a short analysis time. Detection was performed using tandem mass spectrometry in the selected reaction monitoring mode using a triple quadrupole mass spectrometer. Samples were dissolved in ammonium acetate to achieve a transient-isotachophoretic concentration step at the beginning of the separation and to make it possible to inject larger sample volumes, up to 140 nL. Small amounts of tissue from specific regions of the marmoset monkey brain were pretreated using solid-phase extraction as a clean-up and concentrating step. In the striatum we could detect endogenous glutamate, gamma-aminobutyric acid (GABA), acetylcholine and dopamine, as well as the neuropeptides methionine-enkephalin and substance P 1-7 in the same analysis, using only 58 mm3 of brain tissue.


Assuntos
Química Encefálica , Eletroforese Capilar/instrumentação , Eletroforese Capilar/métodos , Espectrometria de Massas/instrumentação , Espectrometria de Massas/métodos , Neuropeptídeos/análise , Neurotransmissores/análise , Acetatos/química , Ácido Acético/química , Animais , Encéfalo/metabolismo , Encéfalo/fisiologia , Callithrix , Eletrofisiologia , Neuropeptídeos/isolamento & purificação , Neurotransmissores/isolamento & purificação , Solventes/química , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...